Mankind Pharma Limited has announced the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director. This appointment, effective from August 10, 2026, is subject to shareholder approval via a postal ballot. Mr. Bafna brings over 30 years of extensive experience in the healthcare and medical devices sector, with a strong track record in managing global businesses and operations.
Board Strengthens Independent Oversight
Mankind Pharma Limited’s Board of Directors, in its meeting held on August 10, 2026, approved the appointment of Mr. Anish Vanraj Bafna as an Additional Director. He will serve in the capacity of a Non-Executive Independent Director. This strategic appointment is based on the recommendation of the Nomination and Remuneration Committee and is effective from August 10, 2026.
Shareholder Approval and Director’s Profile
The appointment of Mr. Bafna for a term of five consecutive years will require the formal approval of the company’s members through a postal ballot, which will be circulated in due course. The company has also obtained a declaration confirming that Mr. Bafna is not debarred from holding the office of a Director by any regulatory authority. Mr. Bafna possesses over 30 years of experience in the healthcare and medical devices sector, having held significant leadership roles, including CEO and Managing Director of Healthium Medtech Limited and leadership positions at Baxter International.
Source: BSE
